Srinagar Observer
Sunday, June 29, 2025
  • Home
  • Top News
  • Kashmir
  • Jammu
  • Business
  • Sports
  • National
  • World
  • Editorial

    The Habitual Shifts

    Assuring Crime Free Society

    Stimulating Young Energy

    An Ethical Denial

    Beating Inflation

    The Timely Exigence

    Extension in Academics

     Aiding Healthcare

    Development in Disguise

    Gender-Free Conviction

  • Edit-Oped
  • ePaper
No Result
View All Result
Srinagar Observer
  • Home
  • Top News
  • Kashmir
  • Jammu
  • Business
  • Sports
  • National
  • World
  • Editorial

    The Habitual Shifts

    Assuring Crime Free Society

    Stimulating Young Energy

    An Ethical Denial

    Beating Inflation

    The Timely Exigence

    Extension in Academics

     Aiding Healthcare

    Development in Disguise

    Gender-Free Conviction

  • Edit-Oped
  • ePaper
No Result
View All Result
Srinagar Observer
No Result
View All Result
Home Business

Five Pharma major companies to collaborate for clinical trial of Oral Anti-Viral drug Molnupiravir

SO NEWS Desk by SO NEWS Desk
June 29, 2021
in Business, Latest
A A
0
Share on FacebookShare on TwitterWhatsApp

RELATED POSTS

Delay in Rotational Headship Policy Draws Concern in Kashmir’s Medical Colleges

Rouble Nagi Art Foundation to Establish Computer Lab at Madrasa Shah Hamdan Tangdar

Hyderabad –  Five pharma major companies of Cipla, Dr Reddy, Emcure, Sun Pharma and its subsidiaries and associate companies and Torrent Pharma on Tuesday announced that they will collaborate for the clinical trial of the investigational oral anti-viral drug Molnupiravir for the treatment of mild COVID-19 in an outpatient setting in India.
Between March and April this year, these five pharma companies had individually entered into a non-exclusive voluntary licensing agreement with Merck Sharp Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 Low and Middle-Income Countries (LMICs).
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India, Hyderabad-based Dr Reddy labs said in a release here.
As per the directive of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization, Dr. Reddy’s will conduct the clinical trial using its product, and the other four pharma companies will be required to demonstrate equivalence of their product to the product used by Dr. Reddy’s in its clinical trial.
Following the clinical trial protocol approval given by the Drugs Controller General of India (DCGI), the clinical trial will be conducted for the treatment of mild COVID-19 in an outpatient setting.
It is expected to take place between June and September this year across India with the recruitment of 1,200 patients.
Such collaboration for a clinical trial is a first of its kind within the Indian pharma industry, and will aim to investigate yet another line of treatment in the collective fight against the COVID-19 pandemic.
On successful completion of the clinical trial, each company will independently approach the regulatory authorities for approval to manufacture and supply Molnupiravir for the treatment of COVID-19 in India.
Molnupiravir is an oral anti-viral that inhibits the replication of multiple RNA viruses including SARS-CoV-2.
It is presently being studied by MSD, through a collaboration with Ridgeback Biotherapeutics, in a Phase III trial for the treatment of non-hospitalized patients with confirmed COVID-19 globally.

Related

ShareTweetSend
SO NEWS Desk

SO NEWS Desk

Related Posts

Delay in Rotational Headship Policy Draws Concern in Kashmir’s Medical Colleges

by SO NEWS Desk
June 28, 2025
0

SRINAGAR, JUNE 28 - A year after the Jammu and Kashmir government issued a landmark order mandating rotational headship in...

Rouble Nagi Art Foundation to Establish Computer Lab at Madrasa Shah Hamdan Tangdar

by SO NEWS Desk
June 27, 2025
0

KARNAH, KUPWARA | JUNE 27, 2025: In a major initiative aimed at bridging the digital divide in border areas, renowned...

Dharti Aaba Abhiyan Day-4: IEC campaign witnesses vibrant community participation in Anantnag

by SO NEWS Desk
June 18, 2025
0

ANANTNAG, JUNE 18: The ongoing 15-day Intensive Information, Education, and Communication (IEC) campaign under the Dharti Aaba Janjatiya Gramin Utkarsh...

Shakti Vijay Brigade Organizes Ex-Servicemen Rally at Tangdhar

by SO NEWS Desk
June 16, 2025
0

Dr Ashfaq Lone Tangdhar, June 16: In a significant outreach initiative, the Shakti Vijay Brigade conducted a large-scale Ex-Servicemen (ESM)...

Faz Lul Haseeb, IAS, Assumes Charge as Commissioner SMC & CEO SSCL

by SO NEWS Desk
June 16, 2025
0

SRINAGAR, JUNE 16: Shri Faz Lul Haseeb, IAS, today formally assumed charge as the Commissioner of Srinagar Municipal Corporation (SMC)...

Next Post

Gold, silver decline on muted global trends

Sarmad Hafeez visits Sher Garhi Complex; Reviews Rs 137 cr restoration, conservation, re-use plan

Digital Edition

Srinagar Observer

Srinagar Observer is an English Newspaper based in Jammu and Kashmir

CATEGORY

  • Business
  • Edit-Oped
  • Editorial
  • Jammu
  • Kashmir
  • Latest
  • National
  • Photo Gallery
  • Sports
  • Top News
  • Uncategorized
  • World

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 9,375 other subscribers

Archives

No Result
View All Result
  • Home
  • About Us
  • Contact Us
  • Advertise

© 2024 Srinagar Observer - Designed by GITS.

No Result
View All Result
  • Home
  • Top News
  • Kashmir
  • Jammu
  • Business
  • Sports
  • National
  • World
  • Editorial
  • Edit-Oped
  • ePaper

© 2024 Srinagar Observer - Designed by GITS.